Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: October 21, 2005
Last updated: August 9, 2013
Last verified: August 2013
Results First Received: March 22, 2013  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Carcinoma
Non-Small-Cell Lung Carcinoma
Head and Neck Neoplasms
Intervention: Drug: AZD2171

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Cediranib 30 mg Cediranib 30mg/Day

Baseline Measures
    Cediranib 30 mg
Overall Participants 
[units: participants]
[units: Years]
Mean (Standard Deviation)
 58.1  (12.32) 
[units: Participants]
Female   4 
Male   15 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Standardised Uptake Value (SUVmax) as Measured by 2-[F-18]-Fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET)   [ Time Frame: Randomisation until Day 22 ]

2.  Secondary:   Change From Baseline in Mean Arterial Blood Pressure (MAP)   [ Time Frame: Randomisation until Day 22 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information